SLC11A1 polymorphisms in inflammatory bowel disease and Mycobacterium avium subspecies paratuberculosis status

doi:10.3748/wjg.v16.i45.5727

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 45

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3941)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-3) series.

Item

Count

PDF

354

HTML

3385

Tables (1-3)

202

Sum=3941

Dec 7, 2010 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Dec 7, 2010; 16(45): 5727-5731
Published online Dec 7, 2010. doi: 10.3748/wjg.v16.i45.5727

Table 1 Genotype and allele frequencies of SLC11A1 1730G>A and 469+14G>C in New Zealand Crohn’s disease and ulcerative colitis patients, and healthy controls n (%)

Phenotype	Genotype			MAF	Allelic P value	Allelic OR (95% CI)
1730G>A	GG	GA	AA	A
CD (n = 495)	474 (96)	21 (4)	0	21 (2)	0.832	1.07 (0.57-2.00)
UC (n = 470)	450 (96)	20 (4)	0	20 (2)	0.827	1.07 (0.57-2.02)
HC (n = 503)	483 (96)	20 (4)	0	20 (2)
469+14G>C	GG	GC	CC	C
CD (n = 495)	265 (54)	192 (39)	38 (8)	268 (27)	0.153	0.83 (0.65-1.07)
UC (n = 451)	245 (54)	171 (38)	35 (8)	241 (27)	0.101	0.81 (0.62-1.04)
HC (n = 486)	238 (49)	204 (42)	44 (9)	292 (30)

MAF: Minor allele frequency; OR: Odds ratio; CI: Confidence interval; CD: Crohn’s disease; UC: Ulcerative colitis; HC: Healthy controls.

Table 2 Genotype frequencies of SLC11A1 1730G>A (rs17235409) in inflammatory bowel disease patients who have used/not used immunomodulators n (%)

Phenotype/immunomodulator status	Genotype			P value	OR (95% CI)
	GG	GA	AA
CD/never used IM (n = 217)	203 (94)	14 (6)	0	0.031	0.38 (0.15-0.95)
CD/have used IM (n = 278)	271 (98)	7 (2)	0
UC/never used IM (n = 356)	336 (94)	20 (6)	0	0.010	0.75 (0.71-0.79)
UC/have used IM (n = 114)	114 (100)	0	0
IBD/never used IM (n = 573)	539 (94)	34 (6)	0	0.002	0.29 (0.13-0.66)
IBD/have used IM (n = 392)	385 (98)	7 (2)	0

OR: Odds ratio; CI: Confidence interval; CD: Crohn’s disease; UC: Ulcerative colitis; IBD: Inflammatory bowel disease; IM: Immunomodulator.

Table 3 Distribution of SLC11A1 469+14G>C genotype by Mycobacterium avium subspecies paratuberculosis status¹ in New Zealand Caucasians n (%)

MAP DNA in blood	Genotype frequency		P value	OR (95% CI)
MAP DNA in blood	GG	GC + CC
Present (n = 150)	66 (44)	84 (56)	0.02	1.56 (1.06-2.29)
Absent (n = 351)	193 (55)	158 (45)

¹Tested by IS900 polymerase chain reaction to detect the presence of Mycobacterium avium subspecies paratuberculosis (MAP) DNA in peripheral blood[20]. OR: Odds ratio; CI: Confidence interval.

Citation: Stewart LC, Day AS, Pearson J, Barclay ML, Gearry RB, Roberts RL, Bentley RW. SLC11A1 polymorphisms in inflammatory bowel disease and Mycobacterium avium subspecies paratuberculosis status. World J Gastroenterol 2010; 16(45): 5727-5731
URL: https://www.wjgnet.com/1007-9327/full/v16/i45/5727.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i45.5727